Ovid Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview

Ovid Therapeutics

07/03/2025 12:43

Ovid Therapeutics Inc OVID.OQ OVID.O is expected to show a rise in quarterly revenue when it reports  results on March 10 (estimated) for the period ending December 31 2024

The New York City-based  company is expected to report a 33.3% increase in revenue to $189.29 thousand from $142 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Ovid Therapeutics Inc is for a loss of 17 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Ovid Therapeutics Inc is $3.50​, above​ its last closing price of $0.52. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.19
-0.20
-0.20
Met
1.9
Jun. 30 2024
-0.20
-0.22
0.12
Beat
154.1
Mar. 31 2024
-0.22
-0.22
-0.17
Beat
22​
Dec. 31 2023
0.25
-0.05
-0.22
Missed
-342.6
​​Sep. 30 2023
-0.19
-0.19
-0.16
Beat
15.2
Jun. 30 2023
-0.20
-0.20
-0.18
Beat
12​
Mar. 31 2023
-0.17
-0.17
-0.19
Missed
-10.9
Dec. 31 2022
-0.17
-0.18
-0.16
Beat
12.2

This summary was machine generated March 7 at 12:43 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)